CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	291.34	347.56	298.26	389.48	211.89	923.03
Short-Term Investments	2,073	1,628	1,606	1,304	1,603	1,456
Cash & Short-Term Investments	2,364	1,976	1,904	1,694	1,815	2,379
Cash Growth	37.36%	3.78%	12.41%	-6.70%	-23.70%	40.75%
Accounts Receivable	-	-	25	200	-	0.31
Other Receivables	-	-	-	6.5	11.2	8.4
Receivables	-	-	25	206.5	11.2	8.71
Prepaid Expenses	7.02	5.95	8.31	7.89	26.01	29.68
Restricted Cash	0.4	3.89	-	-	0.5	-
Total Current Assets	2,372	1,986	1,937	1,908	1,853	2,418
Property, Plant & Equipment	233.66	247.58	277.55	305.94	320.56	312.04
Long-Term Investments	35.9	22.6	12.9	1.97	53.13	-
Other Intangible Assets	-	-	-	0.02	0.07	0.13
Other Long-Term Assets	9.44	9.4	14.45	13.57	16.28	22.2
Total Assets	2,651	2,265	2,242	2,230	2,243	2,752

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	11.31	11.14	14.71	38.15	27.43	14.82
Accrued Expenses	30.71	34.46	39.56	40.67	61.33	77.77
Current Portion of Leases	18.65	18.58	17.29	15.63	15.84	12.16
Current Income Taxes Payable	0.49	1.11	0.45	0.44	0.14	0.72
Current Unearned Revenue	15.19	15.77	3.85	4.11	-	1.01
Other Current Liabilities	56.55	68.06	11.93	9.81	16.38	13.4
Total Current Liabilities	132.9	149.12	87.78	108.79	121.11	119.88
Long-Term Debt	586.2	-	-	-	-	-
Long-Term Leases	178.9	188.17	206.41	223.01	228.18	212.87
Long-Term Unearned Revenue	-	-	12.32	14.01	12.32	12.32
Other Long-Term Liabilities	6.22	6.14	3.44	0.96	5.97	7.34
Total Liabilities	904.22	343.43	309.95	346.77	367.58	352.42

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	3.13	3.09	2.7	2.5	2.44	2.39
Additional Paid-In Capital	3,910	3,862	3,294	2,878	2,735	2,598
Retained Earnings	-2,162	-1,948	-1,366	-999.7	-846.09	-195.92
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	-4.63	4.82	1.84	1.91	-15.65	-5.07
Total Common Equity	1,747	1,922	1,932	1,883	1,875	2,399
Shareholders' Equity	1,747	1,922	1,932	1,883	1,875	2,399
Total Liabilities & Equity	2,651	2,265	2,242	2,230	2,243	2,752

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	783.75	206.75	223.69	238.63	244.02	225.03
Net Cash (Debt)	1,581	1,769	1,680	1,457	1,624	2,154
Net Cash Growth	4.97%	5.29%	15.31%	-10.30%	-24.59%	32.24%
Net Cash Per Share	16.67	19.67	19.92	18.39	20.89	26.79
Filing Date Shares Outstanding	96.69	95.99	85.77	80.28	78.65	77.07
Total Common Shares Outstanding	96.66	95.89	85.74	80.04	78.51	76.99
Working Capital	2,239	1,837	1,849	1,799	1,732	2,298
Book Value Per Share	18.07	20.04	22.53	23.52	23.89	31.17
Tangible Book Value	1,747	1,922	1,932	1,883	1,875	2,399
Tangible Book Value Per Share	18.07	20.04	22.53	23.52	23.89	31.16
Machinery	57.66	56.28	54.4	53.26	49.62	36.25
Construction In Progress	3.22	3.96	6.12	8.86	6.16	52.4
Leasehold Improvements	146.79	146.67	145.85	143.26	141.68	86.74

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error